GLP-2 TRZ – 30mg

GLP-2 TRZ is a dual incretin receptor agonist simultaneously targeting glucagon like peptide 1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) receptors. The same dual GIP/GLP-1 mechanism that distinguishes this compound class from single receptor GLP-1 agonists like Semaglutide and from triple receptor agonists like GLP-3 RTA. Hudson Science’s 30mg formulation delivers the highest concentration presentation in CSD’s GLP-2 TRZ range as a lyophilized vial, providing researchers with the most extended single vial supply volume available within the dual incretin agonist family for long duration protocols or higher dose response evaluations.

The 30mg concentration sits above the Hudson Science 20mg GLP-2 TRZ variant and the 15mg GLP-2 TZ presentation in CSD’s dual incretin agonist range. All delivering identical base compound pharmacology with concentration representing the primary selection variable. The 30mg format is particularly suited to extended research timelines where a single vial supply must cover multiple administrations across a longer observation window, or dose escalation protocols examining dual GIP/GLP-1 receptor co activation at higher concentration points beyond what the 15mg and 20mg presentations support.

The dual GIP and GLP-1 receptor co activation mechanism remains consistent across all GLP-2 TRZ presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside growing research interest in adipose tissue metabolism, bone turnover, and the synergistic incretin response produced when both pathways are activated simultaneously, a combined receptor profile that has made dual incretin agonist compounds among the most actively researched peptide classes in contemporary metabolic and endocrine science.

Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s dual incretin agonist range spans GLP-2 TZ 15mg, GLP-2 TRZ 20mg, and this GLP-2 TRZ 30mg. Allows the opportunity for researchers to use three concentration options within the dual GIP/GLP-1 mechanism from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside GLP-1 receptor agonist compounds and triple incretin agonists in comparative incretin pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.